The Adaptive COVID-19 Treatment Trial (ACTT)

NIH RePORTER · NIH · N01 · $40,199,082 · view on reporter.nih.gov ↗

Abstract

To support randomized, controlled clinical trials to evaluate the safety and efficacy of investigational antiviral drugs against COVID-19.

Key facts

NIH application ID: 10272620
Project number: 75N91019D00024-0-759102000010-1
Recipient: LEIDOS BIOMEDICAL RESEARCH, INC.
Principal Investigator: BETH BASELER
Activity code: N01
Funding institute: NIH
Fiscal year: 2020
Award amount: $40,199,082
Award type: —
Project period: 2020-04-03 → 2025-04-02